Abstract: The I/O circuit of the present invention provides optimal flexibility and performance using a number of different structures and methods. The present invention provides a signal follower circuit for an input pad. In one embodiment, the output buffer is capable of injecting a constant onto a pad during reconfiguration of a configurable system logic circuit. The present invention also provides a circuit for generating a programmable data propagation delay, thereby guaranteeing zero hold time for an arbitrary input register. Zero hold time is accomplished by allowing the user to optimally characterize clock delay to a given input/output circuit. The present invention also provides fast switching between input pads, thereby minimizing data propagation delay between the input pads. Additionally, the present invention reduces time spent in production product test by facilitating the testing of multiple routes with one test configuration.

Abstract: Proteinase inhibitors comprising a Kunitz domain are disclosed. The Kunitz domain comprises a motif of amino acid residues as shown in SEQ ID NO:4, and the sequence of the Kunitz domain is shown in residues 57 through 107 of SEQ ID NO:2. The polypeptide also includes an N-terminal collagen domain in which a von Willebrand domain resides, and is shown in SEQ ID NO: 5. Also disclosed are methods for making the proteinase inhibitors, and expression vectors and cultured cells that are useful within the methods. The proteinase inhibitors may be used as components of cell culture media, in protein purification, and as inhibitors of protease degradation of plasma proteins.

Abstract: Novel tumor necrosis factor ligand polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides may be used within methods relating to immune response, and may also be used in the development of immuno-regulatory therapeutics. Also provided are antibodies, binding proteins, agonists and antagonists of the ligand polypeptides.

Abstract: Proteins consisting of two PDGF-D polypeptide chains, polynucleotides encoding the polypeptides, and materials and methods for making the proteins are disclosed. Each of the polypeptide chains consists of, from amino terminus to carboxyl terminus, the following operably linked segments: P1-P2-h-CH2-CH3; P1 -P2-CH2-CH3; h-CH2-CH3-P2-P1; or CH2-CH3-P2-Pl. Within these polypeptide chains, P1 is a first polypeptide segment as shown in SEQ ID NO: 2 or SEQ ID NO: 4 from amino acid x to amino acid y, wherein x is an integer from 246 to 258, inclusive, and y is an integer from 365-370, inclusive; P2 is a second polypeptide segment consisting of from 4 to 20 amino acid residues; h is an immunoglobulin hinge region or portion thereof; and CH2 and CH3 are CH2 and CH3 domains of an immunoglobulin heavy chain, respectively.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-&agr; at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.

Abstract: The present invention relates to polynucleotide and polypeptide molecules, and variants thereof, for ZSNK16, novel members of the Disintegrin Proteases. The polypeptides, and polynucleotides encoding them, are cell-cell interaction modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the ZSNK16 polypeptides.

Abstract: Systems and methods are defined for facilitating the audit process involving a financial institution, a client of the financial institution, and an accountant. A service provider receives the client's account information from the financial institution upon approval of the client. The financial institution also provides an identification number allowing the accountant to access the information deposited in the service provider. The accountant is provided the identification number in one of a variety of ways allowing the accountant to access the client's information to facilitate an audit process. In this manner, an audit process can be facilitated and reduce the sending of paper copies from the financial institution to the accountant.

Abstract: Transglutaminase polypeptides, polynucleotides encoding them, methods of making them, and methods of using them are disclosed. The polypeptides comprise residues 1-X of SEQ ID NO:2, wherein X is an integer from 462 to 704, inclusive. The compositions and methods of the invention may be used for a variety of purposes in industry, research, and medicine.

Abstract: A programmable input/output memory architecture. The programmable input/output memory cells are disposed in two segments about the periphery of the chip. Each segment has two data buses for separate reading and writing of the configuration register. Each cell is selected and configured according to user specifications. Corresponding memory cells from each segment share the same select line, therefore two bytes of configuration data are accessed together and the data is propagated through both segments approximately concurrently thereby reducing propagation delay.

Abstract: Novel polypeptides, materials and methods for making them, and method of use are disclosed. The polypeptides comprise at least fifteen contiguous amino acid residues of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:9 and may be prepared as polypeptide fusions comprise heterologous sequences, such as affinity tags. The polypeptides and polynucleotides encoding them may be used within a variety of therepeutic, diagnostic, and research applications.

Abstract: Novel polypeptides, materials and methods for making them, and method of use are disclosed. The polypeptides comprise residues 41-150 of SEQ ID NO:2 or residues 32-141 of SEQ ID NO:4, and may be prepared as polypeptide fusions comprise heterologous sequences, such as affinity tags. The polypeptides and polynucleotides encoding them may be used within a variety of therepeutic, diagnostic, and research applications.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp11, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. Novel zacrp11 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp11 protein or fragments thereof.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp13, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. Novel zacrp13 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp13 protein or fragments thereof.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrpl2, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. Novel zacrpl2 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrpl2 protein or fragments thereof.

Abstract: The configurable processor system includes a processor, an internal system bus, and a programmable logic all interconnected via the internal system bus, on a single integrated circuit.

Abstract: The present invention discloses a three-dimensional structure of bovine rhodopsin.

Abstract: The complement system plays an important role in providing resistance to infections and in the pathogenesis of tissue injury. Yet an inappropriate activation of complement can result in a variety of disorders. The present invention provides C1s catalytic site-directed moieties, C1s exosite binding moieties, and bivalent polypeptide inhibitors comprising such moieties, which can be used to treat conditions characterized by inappropriate complement activation.

Abstract: Proteinase inhibitors comprising a Kunitz domain are disclosed. The Kunitz domain comprises a motif of amino acid residues as shown in SEQ ID NO:4, and the sequence of the Kunitz domain is shown in residues 57 through 107 of SEQ ID NO:2. The polypeptide also includes an N-terminal collagen domain in which a von Willebrand domain resides, and is shown in SEQ ID NO: 5. Also disclosed are methods for making the proteinase inhibitors, and expression vectors and cultured cells that are useful within the methods. The proteinase inhibitors may be used as components of cell culture media, in protein purification, and as inhibitors of protease degradation of plasma proteins.

Abstract: The present invention relates to polynucleotide and polypeptide molecules, and variants thereof, for ZSNK10, ZSNK11, and ZSNK12, novel members of the Disintegrin Proteases. The polypeptides, and polynucleotides encoding them, are cell-cell interaction modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the ZSNK10, ZSNK11, and ZSNK12 polypeptides.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-&agr; at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.